Inactive Instrument

Jounce Therapeutics, Inc.

Equities

JNCE

US4811161011

Biotechnology & Medical Research

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Graphite Bio, Inc. Announces Executive Changes CI
Jounce Therapeutics, Inc. Announces Board Changes CI
Jounce Therapeutics, Inc.(NasdaqGS:JNCE) dropped from NASDAQ Composite Index CI
Jounce Therapeutics, Inc.(NasdaqGS:JNCE) dropped from S&P Global BMI Index CI
Jounce Therapeutics, Inc.(NasdaqGS:JNCE) dropped from S&P TMI Index CI
Concentra Biosciences, LLC completed the acquisition of Jounce Therapeutics, Inc. from Tang Capital Management, LLC and others. CI
Redx confirms Jounce deal lapses, Tirupati seals deal AN
Redx Pharma Shares Fall 5% as Merger With Jounce Therapeutics Fails MT
Jounce Therapeutics, Inc. Expects Resignation of Elizabeth Trehu as Chief Medical Officer CI
Sector Update: Health Care Stocks Rise in Late Trading MT
Sector Update: Health Care Stocks Higher in Afternoon Trading MT
European Stock Markets Close Higher Monday as First Citizens BancShares' Planned Acquisition of Silicon Valley Bank Assets, Deposits Eases Banking Crisis Fears MT
Piper Sandler Downgrades Jounce Therapeutics to Neutral From Overweight, Adjusts Price Target to $1.85 From $5 MT
Jounce dumps Redx Pharma for acquisition by Concentra; to cut 84% of jobs RE
Redx Pharma Says Jounce Therapeutics Terminated Merger Deal; Shares Plunge 19% MT
Jounce Therapeutics Agrees to be Acquired by Concentra Biosciences MT
Redx Pharma's bid to buy Jounce snubbed by Concentra's higher offer AN
Jounce Therapeutics, Inc. completed the acquisition of Redx Pharma Plc from a group of sellers and other shareholders. CI
Jounce Therapeutics, Inc. Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian Cancer CI
Sector Update: Health Care Stocks' Late Recovery Stalls MT
Sector Update: Health Care Stocks Moderately Lower MT
Top Midday Gainers MT
Sector Update: Health Care Stocks Retreat Pre-Bell Wednesday MT
Redx Pharma Says Merger Target Jounce Therapeutics Received New Takeover Proposal; Stock Surges 34% MT
Sector Update: Health Care MT
Chart Jounce Therapeutics, Inc.
More charts
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It is engaged in the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Its pipeline is focused on product candidates to address PD-(L)1-inhibitor resistant and PD-(L)1 inhibitor sensitive tumors. Its program, JTX-8064, is a tumor-associated macrophage candidate from its Translational Science platform. JTX-8064 is a monoclonal antibody that binds to Leukocyte Immunoglobulin Like Receptor B2, (LILRB2), which is a cell surface receptor expressed on macrophages and other myeloid cells. JTX-1484 is a monoclonal antibody designed to block human Leukocyte Immunoglobulin Like Receptor B4, (LILRB4) on various myeloid cells. Its product candidate, vopratelimab, is a monoclonal antibody that binds to and activates T cell CO-Stimulator (ICOS). It also develops JTX-1484 and JTX-2134 product candidates.
More about the company
  1. Stock
  2. Equities
  3. Stock Jounce Therapeutics, Inc. - Nasdaq
  4. News Jounce Therapeutics, Inc.
  5. Jounce Therapeutics : Initiates Enrollment of Phase 1 Trial Cohorts of JTX-8064